Skip to main content
Log in

Bioavailability of m-octopamine in man related to its metabolism

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The diminished sympathomimetic pressor activity of monohydroxylated phenylalkylamines after oral administration has been attributed to incomplete enteric absorption. Therefore, urinary excretion of the unchanged drug and its metabolites has been compared after intravenous and oral administration of3H-m-octopamine to eight patients. Identical amounts of3H-activity (80% of the dose) were excreted after the two routes of dosing, so enteric absorption has been assumed to be complete. Significant differences were found in the fraction of free urinarym-octopamine, which amounted to 10.5% of the dose after infusion and 0.58% after oral administration. The only metabolic pathways form-octopamine are deamination and conjugation. Following oral administration the percentage of conjugates was considerably higher than after intravenous infusion. This metabolic pattern appears typical of all phenylalkylamines with a hydroxyl group in themeta position. Ring hydroxylation to catecholamines was not observed. The enzymes mainly responsible for conjugation after oral administration are located in the gut wall. The resulting “first pass effect”, i.e. metabolism prior to the access to the central compartment, can account for the diminished pharmacodynamic effect after dosing by this route.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Axelrod, J.: Enzymatic formation of adrenaline and other catechols from monophenols. Science140 499–500 (1963)

    Google Scholar 

  • Bray, G.: A simple efficient liquid scientillator for counting aqueous solutions in a liquid scintillation counter. Analyt. Biochem.1 279–285 (1960)

    Google Scholar 

  • Conway, W.D., Minatoya, H., Lands, A.M., Shekosky, J.M.: Absorption and elimination profile of isoproterenol. III. The metabolic fate of dlisoproterenol-7-H3 in the dog. J. pharm. Sci.57 1135–1141 (1968)

    Google Scholar 

  • Credner, K. Renwanz, G., Hinze, H.J.: Untersuchungen über das Verhalten des m-Hydroxyphenyl (1)-äthanol) (1)-amin (2) hydrochlorids im Organismus. Naunyn-Schmiedebergs Arch.Pharmak.243 85–90 (1962)

    Google Scholar 

  • Credner, K., Neugebauer, K.: Experimentelle Untersuchungen über die Kreislauf- und Stoffwechselwirkungen des p- und m-Oxyphenylaminoäthynol-HCL. Arzneimittel-Forsch.3 462–465 (1953)

    Google Scholar 

  • Dengler, H. J.: Zur Methodik der Katecholaminbestimmung beim Phaeochromocytom. Ergebn. Labor.-Med.3 55–63 (1967)

    Google Scholar 

  • Dengler, H.J.: Resorption, Verteilung und Ausscheidung von Tritium-markiertem 1-(3,5-Dihydroxyphenyl)-2-isopropylaminoäthanol (Alupent). Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.255 9 (1965)

    Google Scholar 

  • Engelman, K., Jéquier, E., Udenfriend, S., Sjoerdsma, A.: Metabolism of α-methyltyrosine in man: Relationship to its potency as an inhibitor of catecholamine biosynthesis. J. clin. Invest.47 568–576 (1968)

    Google Scholar 

  • Hengstmann, J.H., Konen, W., Konen, C., Eichelbaum, M., Dengler, H.J.: The physiological disposition ofp-octopamine in man. Naunyn-Schmiedebergs Arch. Pharmacol.283 93–106 (1974)

    Google Scholar 

  • Hengstmann, J.H., Weyand, U., Dengler, H.J.: Enteral absorption and metabolism of DL-1-(m-hydroxyphenyl)-2-ethylaminoethanol in the human. Naunyn-Schmiedebergs Arch. Pharmac.274, R51 (1972)

  • Ikeda, M., Levitt, M., Udenfriend, S.: Hydroxylation of phenyl alanine by purified preparations of adrenal and brain tyrosine hydroxylase. Biochem. biophys. Res. Commun.18 482–488 (1965)

    Google Scholar 

  • Jones, R.L., Bory, P., Brown, W.T., Mc.Geer, P.L.: Failure to detect p-methoxyphenylethylamine derivatives in human urine. Canad. J. Biochem.47 185–195 (1969)

    Google Scholar 

  • Kaczmarek, E., Puppe, H.: Klinisch-experimentelle Messungen zur Kreislaufwirkung des Novadrals. Arzneimittel-Forsch.3 208–210 (1953)

    Google Scholar 

  • Pisano, J.J., Crout, J.R., Abraham, D.: Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin. chim. Acta7 285–291 (1962)

    Google Scholar 

  • Richter, D.: The inactivation of adrenaline in vivo in man. J. Physiol. (Lond.)98 361–370 (1940)

    Google Scholar 

  • Ruthven, C.R.J., Sandler, M.: The estimation of 4-hydroxy-3-methoxyphenylglycol and total metadrenalines in human urine. Clin. chim. Acta12 318–324 (1968)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hengstmann, J.H., Konen, W., Konen, C. et al. Bioavailability of m-octopamine in man related to its metabolism. Eur J Clin Pharmacol 8, 33–39 (1975). https://doi.org/10.1007/BF00616412

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00616412

Key words

Navigation